SHANGHAI, China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech, China’s leading provider of pharmaceutical R&D outsourcing services announced today that it has begun moving the first group of scientists to its state-of-the-art Tianjin research facility, which first became operational in December, 2006. Located in the Tianjin Economic and Technical Development Zone (TEDA) (also known as Tai Da), Tianjin PharmaTech is a wholly owned subsidiary of WuXi PharmaTech Co., Ltd.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
The new facility aptly compliments the Shanghai research campus with 130,000 sq. ft. of new laboratory space. Tianjin PharmaTech boasts an even higher advanced equipment ratio than WuXi PharmaTech’s other already very well equipped facilities.
The TEDA Development Zone was one of China’s first state-level development areas and now encompasses an area of over 27 sq. km. With special support for high-tech companies, TEDA and Tianjin are an ideal location for WuXi PharmaTech to plant its seed of future growth.
Often referred to as the ''Gate of Beijing’’, Tianjin is China’s third largest city and offers numerous high quality universities. Drawing from these universities and those of nearby Beijing, Tianjin PharmaTech will benefit from a deep talent pool of qualified researchers.
''The commencement of Tianjin PharmaTech represents new expansion, new government support, a broad talent pool of qualified graduates, and a new state-of-the-art facility that will grow with the needs of our collaborative partners’’, commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. ''I am excited for the unique opportunities and growth prospects our Tianjin facility will offer to our existing and future partners,’' continued Dr. Li.
About WuXi PharmaTech
Founded in 2001, Shanghai-based WuXi PharmaTech is China’s leading drug R&D service company. As a research-driven and customer-focused company, WuXi PharmaTech offers global pharmaceutical and biopharmaceutical companies a diverse, value-added, and fully integrated portfolio of outsourcing services ranging from discovery chemistry, and process chemistry to service biology, bioanalytical chemistry, and large scale GMP manufacturing. WuXi PharmaTech assists its global partners in shorting the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save our clients both time and money. Currently, our client list consists of 19 of the top 20 pharmaceutical, and 8 of the top 10 biopharmaceutical companies. For more information, please visit: http://www.pharmatechs.com .
About Tianjin Economic and Technical Development Zone (TEDA)
The establishment of Tianjin Economic and Technological Development Area (TEDA) was given government approval on December 6, 1984. One of the country’s first state-class development areas, TEDA has developed into one of the country’s most influential hotbeds for high-tech and new industries. But TEDA has a more ambitious goal for the new century: to build ''Asia’s biggest and China’s best modern industrial area in the 21st century’’. To make that dream come true, TEDA has embarked upon another arduous pioneering journey and jump-started diverse projects zeroing in on better investment environment, cityscape and habitability of this young urban area. For more information, please visit: http://www.teda.gov.cn/englishnew/index.jsp .
For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: PR@pharmatechs.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840WuXi PharmaTech Co., Ltd.
CONTACT: Sherry Shao of WuXi, +86-21-5046-4002, or PR@pharmatechs.com
